Abstract
Approximately 183,000 women are diagnosed with breast cancer each year in the United States. Breast cancer is the leading cancer and the second leading cause of mortality in women. Limitations of mammography with regards to breast cancer detection in women with dense breasts have prompted a considerable interest in FDG-PET for diagnosing breast cancer.
As a whole body technique, PET stages not only axillary and internal mammary nodes but also the whole body for unexpected sites of disease.
The value of FDG-PET for predicting patient outcome has been established.
The role of PET/CT for primary diagnosis and axillary lymph node involvement has not been studied. Most frequently, PET and PET/CT are used to restage breast cancer, identify sites of disease recurrence and to characterize equivocal anatomical “abnormalities”. Finally, treatment monitoring is another important indication for PET or PET/CT.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11(11):2101–2111.
Crippa F, Agresti R, Donne VD, Pascali C, Bogni A, Chiesa C, De Sanctis V, Schiavini M, Decise D, Bombardieri E. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan. Tumori. 1997;83(2):542–543.
Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF. Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18(8): 1676–1688.
Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, Schwaiger M. Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18(8): 1689–1695.
Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E. Breast density as a predictor of mammographic detection: comparison of interval-and screen-detected cancers. J Natl Cancer Inst. 2000;92(13):1081–1087.
Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M. Breast imaging with fluorine-18 fluorodeoxy glucose: use and limitations. J Clin Oncol. 2000;18(20):3495–3502.
Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nussle K, Koretz K, Glatting G, Rieber A, Kreienberg R, Buck AC, Reske SN. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28(3):351–358.
Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, Valk PE, Czernin J. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician’s perspective. J Nucl Med. 2001;42(9):1334–1337.
Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. Whole-body 18F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002;43(3):325–329.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Czernin, J., Dahlbom, M., Ratib, O., Schiepers, C. (2004). Breast Cancer. In: Atlas of PET/CT Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18517-5_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-18517-5_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62141-3
Online ISBN: 978-3-642-18517-5
eBook Packages: Springer Book Archive